You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma

  • Technology appraisal guidance
  • Reference number: TA321
  • Published:  22 October 2014
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib [ID605]: final appraisal determination document

Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib [ID605]: final appraisal determination document Melanoma (BRAF V600, unresectable, metastatic) - dabrafenib [ID605]: final appraisal determination document
18 September 2014
(335.48 Kb 37 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 17 September 2014

Back to top